-

06:29:24 PM

LIVE Real Time ABBV Stock Market News

ABBV - Abbvie Inc

04/07/21 9:01 AM

NYSE : ABBV

AbbVie Submits Regulatory Applications for SKYRIZI(R) (risankizumab) in Psoriatic Arthritis to FDA and EMA

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI (R) (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI (R) (risankizumab, 150 mg) to the European Medicines

RHEA-AI

neutral

04/07/21 8:00 AM

NYSE : ABBV

AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. A total of 33 abstracts, including one

RHEA-AI

neutral

04/02/21 5:18 PM

NYSE : ABBV

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in

RHEA-AI

neutral

04/01/21 8:45 AM

NYSE : ABBV

SkinMedica(R) Launches Neck Correct Cream for Neck and Decollete

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica (R) Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and

RHEA-AI

neutral

04/01/21 8:31 AM

NYSE : ABBV

New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ(TM) (upadacitinib) in Psoriatic Arthritis

AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (TM) (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had

RHEA-AI

neutral

03/31/21 8:00 AM

NYSE : ABBV

AbbVie to Host First-Quarter 2021 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through

RHEA-AI

neutral

03/30/21 8:00 AM

NYSE : ABBV

U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist

RHEA-AI

neutral

03/17/21 8:45 AM

NYSE : ABBV

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis

AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in

RHEA-AI

neutral

02/25/21 8:00 AM

NYSE : ABBV

Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

RHEA-AI

neutral

02/24/21 7:14 PM

NYSE : ABBV

HUMIRA(R) (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA (R) (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next